Re-post from Slcimmuno 1) UPCOMING MILESTONES / C
Post# of 72440
Posted On: 10/26/2015 4:53:35 AM
Re-post from Slcimmuno
1) UPCOMING MILESTONES / CATALYSTS
SCIENCE
- Start of B-ABSSSI (Phase 3) (With Fast-Track designation, per QIDP)
- Completion of K (Phase 1) (more dets as to safety, efficacy)
- Initiation of several K phase 2, 2/3 trials (ovarian, pancreatic, AML) (more frequent dosing likely, grant support--addtl Orphan designation/s)
- Meeting w / FDA on K-pediatric retinoblastoma (rare disease)
- Phase 2 B-OM update
- Phase 2 P update/completion
- ABX platform -- progress on anti-fungals, anti-biofilm (MTA signed for B-prophylactic testing), gram-neg compounds; GI targets (Chrons, IBD, H Supportiva)
OPERATIONS
- Financing in place (shelf, Aspire)
- 1st Shareholder meeting (Dec 15... Be it pitchfork or rose petal in feel)
- NASDAQ uplisting (if $2 is maintained)
- Class Action Defense (Legal)
- Partners: still think this is likely farther off... Post Ph III ABSSSI for ABX... And will it be by indication or for whole platform? Kevetrin, the wildcard... As a case study, see CELG-Nurix deal (p53)
https://blogs.shu.edu/cancer/2015/09/30/ubiqu...d-celgene/
2) CURRENT TRIALS
Clinical Trials
Overall - https://clinicaltrials.gov/ct2/results?term=c...rch=Search
1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1
2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3
3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=4
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=5
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product
Company Website:
cellceutix.com
Read More: http://investorshangout.com/post/view?id=3288...z3pUcp0lyb
1) UPCOMING MILESTONES / CATALYSTS
SCIENCE
- Start of B-ABSSSI (Phase 3) (With Fast-Track designation, per QIDP)
- Completion of K (Phase 1) (more dets as to safety, efficacy)
- Initiation of several K phase 2, 2/3 trials (ovarian, pancreatic, AML) (more frequent dosing likely, grant support--addtl Orphan designation/s)
- Meeting w / FDA on K-pediatric retinoblastoma (rare disease)
- Phase 2 B-OM update
- Phase 2 P update/completion
- ABX platform -- progress on anti-fungals, anti-biofilm (MTA signed for B-prophylactic testing), gram-neg compounds; GI targets (Chrons, IBD, H Supportiva)
OPERATIONS
- Financing in place (shelf, Aspire)
- 1st Shareholder meeting (Dec 15... Be it pitchfork or rose petal in feel)
- NASDAQ uplisting (if $2 is maintained)
- Class Action Defense (Legal)
- Partners: still think this is likely farther off... Post Ph III ABSSSI for ABX... And will it be by indication or for whole platform? Kevetrin, the wildcard... As a case study, see CELG-Nurix deal (p53)
https://blogs.shu.edu/cancer/2015/09/30/ubiqu...d-celgene/
2) CURRENT TRIALS
Clinical Trials
Overall - https://clinicaltrials.gov/ct2/results?term=c...rch=Search
1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1
2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3
3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=4
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=5
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product
Company Website:
cellceutix.com
Read More: http://investorshangout.com/post/view?id=3288...z3pUcp0lyb
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
If you try to defend yourself against lies of the board moderators your post will be deleted. Just like the board they claim to be better than!!! Watch who you trust especially the "long term investors" that support the real attackers!
Scroll down for more posts ▼